Previous close | 1,642.50 |
Open | 1,642.50 |
Bid | 1,664.50 x 0 |
Ask | 1,692.00 x 0 |
Day's range | 1,642.50 - 1,642.50 |
52-week range | 1,275.00 - 1,671.00 |
Volume | |
Avg. volume | 76 |
Market cap | N/A |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Finding the right investments can be a challenge, but I've found one FTSE 100 stock that ticks all the boxes for my long-term portfolio. The post I’d buy this FTSE 100 stock without hesitation appeared first on The Motley Fool UK.